FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
By Lori Solomon HealthDay Reporter
MONDAY, Feb. 3, 2025 -- The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow breast cancer.
The approval was granted through Priority Review and Breakthrough Therapy Designation pathways, with HR and HER status determined by an FDA-approved test. Additionally, patients had to have had disease progression after one or more endocrine therapies.
Results from the DESTINY-Breast06 phase 3 trial showed that Enhertu demonstrated superiority compared with chemotherapy. Enhertu showed a significant reduction in the risk for disease progression or death versus chemotherapy (hazard ratio, 0.64) in the overall trial population of patients with chemotherapy-naive HER2-low or HER2-ultralow metastatic breast cancer. Patients randomly assigned to Enhertu had a median progression-free survival of 13.2 months compared with 8.1 months seen for those assigned to chemotherapy. Overall, the confirmed objective response rate was 62.6 percent for Enhertu versus 34.4 percent for chemotherapy.
"Building on the practice-changing previous approvals for Enhertu, this new approval brings this important medicine to an earlier treatment setting and a broader patient population with HER2-expressing metastatic breast cancer," Dave Fredrickson, executive vice president of the Oncology Haematology Business Unit at AstraZeneca, said in a statement. "The approval also highlights the importance of testing metastatic breast cancer tumors for detectable staining with a standard immunohistochemistry test to identify those who may be eligible for treatment with Enhertu following endocrine therapy."
Approval of Enhertu was granted to AstraZeneca and Daiichi Sankyo.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Racialized Economic Segregation Linked to Advanced Cancer Diagnosis
FRIDAY, Aug. 1, 2025 -- People living in racially and economically segregated neighborhoods are more likely to be diagnosed with advanced-stage breast and cervical cancer...
Changes in Missouri Law Linked to Increased Breast Cancer Screening Rates
THURSDAY, July 31, 2025 -- Changes in Missouri law expanding breast cancer screening coverage have led to increased screening rates among Medicaid patients and an increased...
AI Correctly Localized Almost One-Third of Interval Cancers on Screening Digital Breast Tomosynthesis
THURSDAY, July 31 Aug. 1, 2025 -- Artificial intelligence (AI) correctly localized nearly one-third of interval cancers on retrospective evaluation of screening digital breast...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.